Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Quinapril: a new second-generation ACE inhibitor.

A B Cetnarowski-Cropp1

  • 1Cardiology Branch, National Heart, Lung, and Blood Institute, Warren Grant Magneson Clinical Center, Bethesda, MD 20892.

DICP : the Annals of Pharmacotherapy
|May 1, 1991
PubMed
Summary

Quinapril, a new angiotensin-converting enzyme (ACE) inhibitor, is effectively absorbed and metabolized to quinaprilat. It demonstrates comparable antihypertensive efficacy and safety to other ACE inhibitors, including for congestive heart failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of cimetidine administration on the pharmacokinetics of pirmenol.

Journal of clinical pharmacology·1992
Same author

Therapeutic potential of two over-the-counter thyroid hormone preparations.

DICP : the annals of pharmacotherapy·1990
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Quinapril is a novel non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
  • It is hydrolyzed to an active diacid metabolite, quinaprilat, which is more potent than the parent drug.

Purpose of the Study:

  • To characterize the pharmacokinetic and pharmacodynamic properties of quinapril.
  • To evaluate its efficacy and safety as an antihypertensive agent and in treating congestive heart failure (CHF).

Main Methods:

  • Pharmacokinetic analysis of quinapril and quinaprilat absorption, metabolism, and excretion.
  • Clinical evaluation of antihypertensive efficacy and adverse reactions compared to enalapril and captopril.
  • Preliminary assessment in patients with CHF.

Main Results:

Related Experiment Videos

  • Quinapril is approximately 60% absorbed orally, unaffected by food, and excreted renally as quinaprilat.
  • Quinaprilat has a 3-hour half-life, prolonged in renal dysfunction and in cirrhosis patients.
  • Antihypertensive efficacy and adverse event profile are similar to enalapril and captopril; preliminary CHF data are positive.

Conclusions:

  • Quinapril is an effective ACE inhibitor with favorable pharmacokinetics, suitable for once-daily dosing.
  • It represents a therapeutic alternative for hypertension and potentially for CHF treatment.